Merck to Acquire Immune Design for its Technologies for $300M

 Merck to Acquire Immune Design for its Technologies for $300M

Merck to Acquire Immune Design for its Technologies for $300M

Shots:

  • Merck acquires Immune Design, in all stock transaction for $5.85/share in cash making total deal value ~ $300M. The transaction is expected to close in Q2’19
  • The focus of the agreement is to develop and commercialize immune vaccines using Immune Design’s in vivo technologies i.e GLAAS and ZVex against cancer and infectious diseases
  • GLA Adjuvant Systems (GLAAS) is an in vivo Glucopyranosyl Lipid A (GLA) based platform that binds TLR4 receptor activating DCs to produce cytokines and chemokines activating Th1-type immune response. ZVex is a delivery system designed for developing T-Cells targeting tumor cells  

Click here to read full press release/ article | Ref: Merck | Image: Twitter


Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post